Tirellizumab combined with carboplatin and albumin-paclitaxel neoadjuvant therapy+surgery for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Dec 2024: Trial started, NCT07267286
  2. 5 Dec 2025: Trial registered, NCT07267286

The trials

NCT07267286: Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma (HNC-SYSU-005)

State
Under way
Phase
Phase 2
People
60 planned
Started
15 Dec 2024
Primary completion
31 Aug 2028
Arms
Tirellizumab combined with TP neoadjuvant therapy combined with surgery
Results
None posted
  1. 15 Dec 2024: Trial started
  2. 5 Dec 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.